Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2022
Price :
$35
*
At a glance
- Drugs Zolmitriptan (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Amneal Pharmaceuticals; IMPAX Laboratories
- 01 Oct 2022 Primary endpoint (Pain-free status at 2 hours post treatment) has not been met, according to Results published in the Headache.
- 01 Oct 2022 Status changed to discontinued.
- 01 Oct 2022 Results published in the Headache